SharpePoint’s Definium Therapeutics DFTX Stock Holding History

SharpePoint’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$470K	Hold	10,000	–	–	0.24%	62
2026 Q1	$189K	Sell	10,000 -135	-1%	-$2.29K	0.11%	85
2025 Q4	$136K	Buy	+10,135	New	+$125K	0.08%	83
2025 Q3	–	Sell	-10,165	Closed	-$66K	–	44
2025 Q2	$66K	Hold	10,165	–	–	0.07%	43
2025 Q1	$64K	Hold	10,165	–	–	0.06%	76
2024 Q4	$70.7K	Buy	+10,165	New	+$69.9K	0.06%	72

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SharpePoint's DFTX Position: Q2 2026 in Review

SharpePoint held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 10,000 shares worth $470K. The position accounts for 0.24% of the portfolio, ranked #62.

SharpePoint first reported a position in DFTX in Q4 2024 and has held it in 6 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

SharpePoint held 10,000 shares of Definium Therapeutics worth $470K as of Q2 2026.
SharpePoint left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up 0.24% of SharpePoint's portfolio in Q2 2026, its #62 holding.
SharpePoint first reported a position in Definium Therapeutics in Q4 2024 and has held it in 6 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on SharpePoint's 13F filing for Q2 2026, filed 29 Jul 2026.